Skip to main content
. Author manuscript; available in PMC: 2011 Apr 1.
Published in final edited form as: J Hypertens. 2010 Apr;28(4):806–816. doi: 10.1097/HJH.0b013e3283358b6e

Fig. 4.

Fig. 4

ICV administration of LPS increased hypothalamic tissue TNF-α (A) and COX-2 (B) mRNA expression, and both were significantly reduced by continuous ICV infusion of tempol and SB203580. ICV LPS also significantly increased cerebrospinal fluid (CSF) level of TNF-α (C) and PGE2 (D). ICV infusion of tempol and SB203580 reduced the LPS-induced increases in CSF TNF-α and PGE2; the COX-2 inhibitor NS398 reduced the LPS-induced increase in CSF PGE2. *P<0.05 versus ICV aCSF, †P<0.05, ICV Treatment + ICV LPS versus ICV LPS alone.